These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 6580983)

  • 1. HLA-DR associations with Graves' disease in eastern Hungary.
    Stenszky V; Kozma L; Balazs C; Farid NR
    Clin Invest Med; 1983; 6(3):181-4. PubMed ID: 6580983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity by cluster analysis techniques of Graves' patients typed for HLA DR and IgG heavy chain markers.
    Frecker MF; Preus M; Kozma L; Krasrits E; Stenszky V; Balazś C; Farid NR
    Mol Biol Med; 1986 Feb; 3(1):63-71. PubMed ID: 3083192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of HLA antigens in the manifestation and course of Graves' disease.
    Stenszky V; Kozma L; Balazś C; Bear JC; Farid NR
    Mol Biol Med; 1986 Feb; 3(1):53-62. PubMed ID: 3485758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DR3 and HLA-DR5 associated thyrotoxicosis--two different types of toxic diffuse goiter.
    Schleusener H; Schernthaner G; Mayr WR; Kotulla P; Bogner U; Finke R; Meinhold H; Koppenhagen K; Wenzel KW
    J Clin Endocrinol Metab; 1983 Apr; 56(4):781-5. PubMed ID: 6131902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic factors in Graves' ophthalmopathy.
    Frecker M; Stenszky V; Balazs C; Kozma L; Kraszits E; Farid NR
    Clin Endocrinol (Oxf); 1986 Nov; 25(5):479-85. PubMed ID: 3113776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological and molecular studies of HLA in Sardinian patients with Graves' disease.
    La Nasa G; Martino E; Carcassi C; Mulargia M; Floris L; Vacca A; Baldini G; Orrù S; Ledda A; Grasso L
    Dis Markers; 1991; 9(6):307-12. PubMed ID: 1823309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of HLA antigen BW35 with severe Graves' ophthalmopathy.
    Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ; Sanford CA
    Invest Ophthalmol Vis Sci; 1983 Jan; 24(1):124-7. PubMed ID: 6600737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of IgG heavy-chain allotypes (Gm) with Graves' disease in Hungary.
    Kozma L; Stenszky V; Kraszits E; Balazs C; Farid NR
    Exp Clin Immunogenet; 1985; 2(3):154-7. PubMed ID: 3939975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of human leukocyte D locus related antigens in Graves' disease.
    Farid NR; Sampson L; Noel EP; Barnard JM; Mandeville R; Larsen B; Marshall WH; Carter ND
    J Clin Invest; 1979 Jan; 63(1):108-13. PubMed ID: 105012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA and Graves' disease: an association with HLA-DRw3.
    Allannic H; Fauchet R; Lorcy Y; Heim J; Gueguen M; Leguerrier AM; Genetet B
    J Clin Endocrinol Metab; 1980 Oct; 51(4):863-7. PubMed ID: 6932402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graves' ophthalmopathy, eye muscle antibodies and HLA antigens.
    Balazs C; Bokk A; Molnar I; Stenszky V; Farid NR
    Exp Clin Immunogenet; 1989; 6(2):190-2. PubMed ID: 2629892
    [No Abstract]   [Full Text] [Related]  

  • 12. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
    de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Basedow's disease and mitral valve prolapse].
    Kahaly G; Erbel R; Mohr-Kahaly S; Zenker G; von Olshausen K; Krause U; Beyer J
    Dtsch Med Wochenschr; 1987 Feb; 112(7):248-53. PubMed ID: 3493129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of immune damage in Graves' ophthalmopathy.
    Hiromatsu Y; Wang PW; Wosu L; How J; Wall JR
    Horm Res; 1987; 26(1-4):198-207. PubMed ID: 3596469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-DR4 associated response to corticosteroids in Graves' ophthalmopathy patients.
    van der Gaag R; Wiersinga WM; Koornneef L; Mourits MP; Prummel MF; Berghout A; de Vries RR; Schreuder GM; D'Amaro J
    J Endocrinol Invest; 1990 Jun; 13(6):489-92. PubMed ID: 2258577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-DRB1*03 is a susceptibility gene in patients with Graves' disease with and without ophthalmopathy.
    Yarman S; Oguz F; Carin M
    Int J Immunogenet; 2007 Feb; 34(1):23-5. PubMed ID: 17284224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Graves' disease. Predominance of the DRw3 antigen (author's transl)].
    Allanic H; Fauchet R; Lorcy Y; Heim J; Guéguen M; Leguerrier AM; Genetet B
    Nouv Presse Med; 1980 Jun; 9(26):1823-6. PubMed ID: 6893077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of autoimmune ophthalmopathy from Graves' hyperthyroidism by analysis of genetic markers.
    Kendall-Taylor P; Stephenson A; Stratton A; Papiha SS; Perros P; Roberts DF
    Clin Endocrinol (Oxf); 1988 Jun; 28(6):601-10. PubMed ID: 3254259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetics of Graves' disease: HLA and disease susceptibility.
    Stenszky V; Kozma L; Balázs C; Rochlitz S; Bear JC; Farid NR
    J Clin Endocrinol Metab; 1985 Oct; 61(4):735-40. PubMed ID: 3861611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Human leukocyte antigen (HLA) complex and anti-thyroidal antibodies in Graves' disease].
    Lacka K; Kordel M; Gembicki M
    Pol Tyg Lek; 1989 Feb 13-20; 44(7-8):179-81. PubMed ID: 2682567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.